Bob Lutz
Company: Iksuda Therapeutics
Job title: Chief Scientific Officer
Seminars:
Session Chair’s Opening Remarks 3:10 pm
Novel Payloads as the New Value Driver for ADCs Why are new payloads needed? What new payloads are on the horizon? Case Study: Focusing on Iksuda’s novel protein alkylator (ProAlk) payloadRead more
day: Day One P3
Novel & Dual Payloads: Assessing Linker Conjugation Technologies That Encourage Flexibility in Payloads 3:50 pm
Evaluating the right ratios, the advantages of releasing drugs in specific ratios, and which combination of drugs make sense when considering dual payloads Discussing the parameters of small molecule degraders and how that lends them to make good payloads Advancing cytoxic or immune-stimulating payloads with novel MoAsRead more
day: Day One P3
Increasing Tissue Penetration & Limiting Immunogenicity: Differentiating Through Novel Conjugate Design 2:10 pm
Targeting proteins expressed in a larger number of cancers versus receptors predominantly expressed in solid tumor subsets Increasing tissue penetration propensity to achieve more significant internalization and intracellular exposure to the payload with smaller proteins Leveraging reduced screening cycles required to optimize linker chemistry with smaller proteins, and modulatory to conjugate different payload typesRead more
day: Conference Day Two
ADC Deal-Making: Will Success Lead to More Success? 2:45 pm
Discussing opportunity for and examples of creative deal structures across ADCs For payloads: Do you need the full ADC payload for a deal? For linkers: What drives deals with different types of linkers? For target discovery: What are the differences in deal structure versus linkers and payloads? Sharing guidance to progress from a research collaboration…Read more
day: Conference Day Two
Chair’s Closing Remarks 3:20 pm
day: Conference Day Two